The most important adverse effect was lower leg edema.<h4>Conclusion</h4>The combination therapy of amantadine, a monoamine oxidase type B-inhibitor and a dopamine agonist is an alternate therapeutic approach that may be able to prevent dyskinesia and fluctuations by drug pharmacokinetics and synergistic effects, and may postpone or reduce the amount of levodopa. This evidence concerns the gene MAOB and Dyskinesia.